邓柳枝;叶青剑;李小毛;

• 1:中山大学附属第三医院妇科

摘要(Abstract)：

目的:探讨孕酮或左炔诺孕酮宫内缓释系统(Progesterone-IUS或LNG-IUS)治疗子宫内膜癌的方案、临床疗效和安全性。方法:收集2002年1月至2012年6月国内外杂志公开发表的Progesterone-IUS或LNG-IUS与子宫内膜癌相关的个案报道共41例。分析单用Progesterone-IUS,LNG-IUS及LNG-IUS联合口服孕激素治疗子宫内膜癌的有效率、安全性。结果:Progesterone-IUS治疗的12例G1ⅠA期子宫内膜癌病例,6个月后治疗有效率为63.6%,12个月时有效率为75%。LNG-IUS治疗的24例病例中,13例单用LNG-IUS,治疗有效率38.5%;LNG-IUS联合口服孕激素11例,有效率为81.8%;13例年龄<40岁,治疗有效率76.9%;11例≥40岁,有效率36.4%。结论:单用Progesterone-IUS或LNG-IUS治疗早期子宫内膜癌有一定疗效,LNG-IUS联合口服孕激素可提高有效率,但存在风险。

关键词(KeyWords)： 癌,子宫内膜样;左炔诺孕酮;子宫内膜;增生;子宫内膜增生;治疗学;孕激素类

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 邓柳枝;叶青剑;李小毛;

DOI: 10.13283/j.cnki.xdfckjz.2013.02.017

参考文献(References)：

• [1]Montz FJ,Bristow RE,Bovicelli A,et al.Intrauterine pro-gesterone treatment of early endometrial cancer[J].Am JObstet Gynecol,2002,186(4):651-657
• [2]Tanmahasamut P,Wongwananuruk T.Challenging regimenfor long-term conservative treatment of endometrial adeno-carcinoma in young women:a case report and review of theliterature[J].Case Rep Oncol,2010,3(3):380-385
• [3]Giannopoulos T,Butler-Manuel S,Tailor A.Levonorgestrel-releasing intrauterine system(LNG-IUS)as a therapy forendometrial carcinoma[J].Gynecol Oncol,2004,95(3):762-764
• [4]Dhar KK,NeedhiRajan T,Koslowski M,et al.Is levonorg-estrel intrauterine system effective for treatment of earlyendometrial cancer?Report of four cases and review of theliterature[J].Gynecol Oncol,2005,97(3):924-927
• [5]Bahamondes L,Ribeiro-Huguet P,de Andrade KC,et al.Levonorgestrel-releasing intrauterine system(Mirena)as atherapy for endometrial hyperplasia and carcinoma[J].Acta Obstet Gynecol Scand,2003,82(6):580-582
• [6]Cade TJ,Quinn MA,Rome RM,et al.Progestogen treat-ment options for early endometrial cancer[J].BJOG,2010,117(7):879-884
• [7]李瑜,滕芳,傅士龙,等.左炔诺孕酮宫内缓释系统治疗子宫内膜癌1例[J].南京医科大学学报(自然科学版),2010,30(5):728-730
• [8]Wildemeersch D,Anderson E,Lambein K,et al.Successfultreatment of early endometrial carcinoma by local deliveryof levonorgestrel:a case report[J].Obstet Gynecol Int,2010,2010:431950
• [9]Vandenput I,Van Eygen K,Moerman P,et al.Ineffectiveattempt to preserve fertility with a levonorgestrel-releasingintrauterine device in a young woman with endometrioidendometrial carcinoma:a case report and review of the lit-erature[J].Eur J Gynaecol Oncol,2009,30(3):313-316
• [10]Fambrini M,Bargelli G,Peruzzi E,et al.Levonorgestrel-releasing intrauterine system alone as primary treatmentin young women with early endometrial cancer:case re-port[J].J Minim Invasive Gynecol,2009,16(5):630-633
• [11]Abu J,Brown L,Ireland D.Endometrial adenocarcinomafollowing insertion of the levonorgestrel-releasing intrau-terine system(mirena)in a 36-year-old woman[J].Int JGynecol Cancer,2006,16(3):1445-1447
• [12]Jones K,Georgiou M,Hyatt D,et al.Endometrial adeno-carcinoma following the insertion of a Mirena IUCD[J].Gynecol Oncol,2002,87(2):216-218
• [13]Kresowik J,Ryan GL,Van Voorhis BJ.Progression of a-typical endometrial hyperplasia to adenocarcinoma despiteintrauterine progesterone treatment with the levonorg-estrel-releasing intrauterine system[J].Obstet Gynecol,2008,111(2 Pt 2):547-549
• [14]Flemming R,Sathiyathasan S,Jackson A.Endometrioidadenocarcinoma after insertion of a levonorgestrel-relea-sing intrauterine system[J].J Minim Invasive Gynecol,2008,15(6):771-773
• [15]Duska LR,Garrett A,Rueda BR,et al.Endometrial canc-er in women 40 years old or younger[J].Gynecol Oncol,2001,83(2):388-393
• [16]Gitsch G,Hanzal E,Jensen D,et al.Endometrial cancerin premenopausal women 45 years and younger[J].Ob-stet Gynecol,1995,85(4):504-508
• [17]Lee NK,Cheung MK,Shin JY,et al.Prognostic factors foruterine cancer in reproductive-aged women[J].ObstetGynecol,2007,109(3):655-662
• [18]Tran BN,Connell PP,Waggoner S,e al.Characteristicsand outcome of endometrial carcinoma patients age 45years and younger[J].Am J Clin Oncol,2000,23(5):476-480
• [19]Hanekamp EE,Gielen SC,van Oosterhoud SA,et al.Pro-gesterone receptors in endometrial cancer invasion andmetastasis:development of a mouse model[J].Steroids,2003,68(10-13):795-800
• [20]ESHRE Capri Workshop Group.Intrauterine devices andintrauterine systems[J].Hum Reprod Update,2008,14(3):197-208
• [21]Andersson K,Mattsson LA,Rybo G,et al.Intrauterine re-lease of levonorgestrel——a new way of adding progesto-gen in hormone replacement therapy[J].Obstet Gynecol,1992,79(6):963-967
• [22]Boon J,Scholten PC,Oldenhave A,et al.Continuous in-trauterine compared with cyclic oral progestin administra-tion in perimenopausal HRT[J].Maturitas,2003,46(1):69-77
• [23]Raudaskoski T,Tapanainen J,Tomas E,et al.Intrauterine10 microg and 20 microg levonorgestrel systems in postm-enopausal women receiving oral oestrogen replacementtherapy:clinical,endometrial and metabolic response[J].BJOG,2002,109(2):136-144
• [24]Wildemeersch D,Dhont M.Treatment of nonatypical andatypical endometrial hyperplasia with a levonorgestrel-re-leasing intrauterine system[J].Am J Obstet Gynecol,2003,188(5):1297-1298
• [25]Vereide AB,Arnes M,Straume B,et al.Nuclear morpho-metric changes and therapy monitoring in patients withendometrial hyperplasia:a study comparing effects of in-trauterine levonorgestrel and systemic medroxyprogester-one[J].Gynecol Oncol,2003,91(3):526-533
• [26]Varma R,Soneja H,Bhatia K,et al.The effectiveness of alevonorgestrel-releasing intrauterine system(LNG-IUS)in the treatment of endometrial hyperplasia——a long-term follow-up study[J].Eur J Obstet Gynecol ReprodBiol,2008,139(2):169-175
• [27]廖瑜,黎清,李依芬,等.子宫内膜癌临床及MRI分期与手术病理分期的对比研究[J].广东医学,2012,33(4):472-473
• [28]Dijkhuizen FP,Mol BW,Brolmann HA,et al.The accura-cy of endometrial sampling in the diagnosis of patientswith endometrial carcinoma and hyperplasia:a meta-anal-ysis[J].Cancer,2000,89:1765-1772